Business Wire

Builder.ai Strengthens Leadership with Craig Saunders from Amazon as New Vice President of Artificial Intelligence

11.6.2024 14:00:00 EEST | Business Wire | Press release

Share

Builder.ai, the AI-powered composable software platform that allows every business and entrepreneur to become digitally powered, is excited to announce the appointment of Craig Saunders as Vice President of Artificial Intelligence. Craig Saunders, a powerhouse in the AI industry, joins Builder.ai from Amazon, where he spent seven transformative years within the Artificial General Intelligence (AGI) organisation.

During his tenure at Amazon, Craig made a significant impact by pioneering technologies for Alexa. He led research and engineering teams building foundational Knowledge Graphs for General Q&A on Alexa, established partnerships with leading universities, and his teams launched challenges within the academic community such as FEVER (Fact Extraction and Verification) to move the state of the art forward on factual accuracy of knowledge graphs. His leadership extended to Natural Language Understanding, including use of seq2seq models in Alexa, and formed the team that federated across multiple Alexa Q&A systems. In 2022, Craig led teams that were building the next generation of textual Large Language Models for Amazon, and advanced personalisation for Alexa.

“Craig’s remarkable achievements in AI - and his visionary approach to multi disciplinary, multi modal AI will enable us to propel Natasha and our AI capabilities to newer frontiers and allow us to drive an even richer customer experience,” said Sachin Dev Duggal, Founder & Chief Wizard, Builder.ai. “His expertise is not just in technology, but in fostering scaled innovation that resonates with customers on a global scale. I’m thrilled to have Craig join the team and excited to see what he and the team add to the Platform and Natasha’s capabilities.”

In his new role, Saunders will lead the AI teams at Builder.ai, focusing on scaling and expanding the company's existing AI capabilities, including Natasha, the world’s first AI product manager, and its new Code Generation System, which automates the transition from a user conversation directly to working code. His expertise will be instrumental in propelling Builder.ai to deliver even more for their customers through tailored software solutions with unprecedented efficiency.

“Joining Builder.ai feels like a natural progression in my career, allowing me to further push the boundaries of AI and machine learning solutions,” adds Craig Saunders. “I’m excited to be a part of the development of cutting-edge AI solutions that will not only transform the way software is created but also empower our customers to achieve their ambitious business goals.”

Craig received a PhD in Machine Learning from the University of London in 2000 and continued in the education sector, working nine years as an academic faculty at Royal Holloway, University of London and the University of Southampton. Utilising his expertise and knowledge, he transitioned to a career at Xerox where he delivered machine learning solutions across diverse industries including transportation, healthcare, and finance. Additionally, Craig has successfully published over 70 academic papers in leading conferences and journals, and holds several patents.

Established in 2016, Builder.ai leads the industry with its AI-powered composable software platform, allowing anyone with an idea to develop an app (web or mobile) more quickly and affordably. By decomposing software into reusable Lego-like features and combining them with cutting-edge AI and a patented software assembly line, Builder.ai has demonstrated global success in enabling customers of all sizes to adopt a software-first approach.

About Builder.ai

Builder.ai® is an AI-powered composable software platform for every idea and company globally. The AI-powered assembly line integrates Lego-like reusable features with Building Blocks™ automation to minimise human effort, leverages a verified network of experts to significantly extend development capabilities, and produces apps with a nearly zero failure rate at a fraction of the cost and time of traditional software development.

Led by serial entrepreneur Sachin Dev Duggal, Builder.ai is reshaping the construction and operation of software with a suite of products and services, including BUILDER STUDIO, BUILDER CLOUD, BUILDER NOW, and STUDIO STORE. Builder.ai was featured on the 2023 Fast Company list of Most Innovative Companies, received the “Hottest AI Startup” and 2022’s “Hottest Scale-Up” awards at the Europas for Europe's successful tech startups, and won the Best COVID-19 Innovation for Recovery at CogX. It was also named 'Visionary' in the 2021 Gartner® Magic Quadrant™ for Multi-experience Development Platforms. Builder.ai is headquartered in London, with employees and hubs in Delhi NCR, Singapore, Los Angeles, Salt Lake City, Sophia Antipolis, and Dubai. For more information, visit Builder.ai.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240611122778/en/

Contacts

Stephanie.lowenthal@builder.ai

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 14:30:00 EEST | Press release

Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress, showed the study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS). Gastric cancer is a leading cause of cancer-related death worldwide, and outcomes are particularly poor once the disease is advanced.1 Because treatment options are limited for people whose cancer continues to progress after multiple therapies, there is a significant need for new targeted therapies.2 CLDN18.2, a protein found at abnormally high levels on the surface of certain cancer cells, has emerged as a key biomarke

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye